Donald Bobo - Edwards Lifesciences President
President
Mr. Donald E. Bobo Jr. is Corporationrationrate Vice President Strategy and Corporationrationrate Development of Edwards Lifesciences Corporationration Mr. Bobo was Corporationrationrate Vice President since 2007 and is responsible for Edwards corporate strategy and corporate development functions. In addition, Mr. Bobo has executive responsibility for the Companys disease awareness and heart failure initiatives, as well as the healthcare solutions and commercial services team since 2015.
Age | 62 |
Tenure | 9 years |
Phone | 949 250 2500 |
Web | https://www.edwards.com |
Edwards Lifesciences Management Efficiency
The company has Return on Asset (ROA) of 0.1225 % which means that for every $100 of assets, it generated a profit of $0.1225. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.2234 %, which means that it produced $0.2234 on every 100 dollars invested by current stockholders. Edwards Lifesciences' management efficiency ratios could be used to measure how well Edwards Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.1 in 2024. Return On Capital Employed is likely to drop to 0.14 in 2024. At this time, Edwards Lifesciences' Intangibles To Total Assets are fairly stable compared to the past year. Fixed Asset Turnover is likely to climb to 4.91 in 2024, whereas Debt To Assets are likely to drop 0.07 in 2024.The company reports 694.9 M of total liabilities with total debt to equity ratio (D/E) of 0.11, which may suggest the company is not taking enough advantage from financial leverage. Edwards Lifesciences Corp has a current ratio of 3.75, indicating that it is in good position to pay out its debt commitments in time. Debt can assist Edwards Lifesciences until it has trouble settling it off, either with new capital or with free cash flow. So, Edwards Lifesciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Edwards Lifesciences Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Edwards to invest in growth at high rates of return. When we think about Edwards Lifesciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
Found 14 records | PRESIDENT Age | ||
Stuart Hockridge | Align Technology | 52 | |
Yuval Shaked | Align Technology | 44 | |
Markus Sebastian | Align Technology | N/A | |
Sian Roberts | Align Technology | N/A | |
Jennifer Erfurth | Align Technology | 45 | |
Zelko Relic | Align Technology | 59 | |
Sreelakshmi Kolli | Align Technology | 49 | |
Christopher Puco | Align Technology | 56 | |
Lynn Pendergrass | Align Technology | 55 | |
Brad Jergenson | Align Technology | N/A | |
Simon Beard | Align Technology | 57 | |
Jennifer Olson | Align Technology | 40 | |
Julie Tay | Align Technology | 51 | |
Raj Pudipeddi | Align Technology | 45 |
Management Performance
Return On Equity | 0.22 | ||||
Return On Asset | 0.12 |
Edwards Lifesciences Corp Leadership Team
Elected by the shareholders, the Edwards Lifesciences' board of directors comprises two types of representatives: Edwards Lifesciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Edwards. The board's role is to monitor Edwards Lifesciences' management team and ensure that shareholders' interests are well served. Edwards Lifesciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Edwards Lifesciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Paul LaViolette, Independent Director | ||
John Cardis, Independent Director | ||
Wesley Schack, Presiding Independent Director | ||
Larry Wood, Corporate Vice President - Transcatheter Aortic Valve Replacement | ||
Leslie Heisz, Independent Director | ||
Catherine Szyman, Corporate Vice President - Critical Care | ||
Arnold Pinkston, Corporate Counsel | ||
Barbara McNeil, Independent Director | ||
Steven Loranger, Independent Director | ||
Scott Ullem, Chief Financial Officer, Corporate Vice President | ||
Patrick Verguet, Corporate VP of EMEA, Canada and Latin America | ||
Kieran Gallahue, Independent Director | ||
Nicholas Valeriani, Independent Director | ||
Heisz Stone, Independent Director | ||
Mark Wilterding, Vice Relations | ||
MD FACC, Corporate Officer | ||
Angela Fuente, Director Engineering | ||
Martha Marsh, Lead Independent Director | ||
Daveen Chopra, Corporate Vice President - Surgical Structural Heart | ||
Huimin Wang, Corporate Vice President - Japan, Asia and Pacific | ||
JeanLuc Lemercier, Corporate Vice President - EMEA (Europe, Middle East and Africa) | ||
Christine McCauley, Corporate Resources | ||
William Link, Independent Director | ||
Gary Sorsher, Senior Compliance | ||
Ramona Sequeira, Independent Director | ||
Bernard Zovighian, Corporate Vice President -Surgical Heart Valve Therapy | ||
David Erickson, Vice President - Investor Relations | ||
Daniel Lippis, Greater Japan | ||
Donald Bobo, Corporate Vice President - Strategy and Corporate Development | ||
Todd Brinton, Co Officer | ||
Dirksen Lehman, Corporate Affairs | ||
Finn Haley, Vice Development | ||
Michael Mussallem, Chairman of the Board, Chief Executive Officer |
Edwards Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Edwards Lifesciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.22 | ||||
Return On Asset | 0.12 | ||||
Profit Margin | 0.23 % | ||||
Operating Margin | 0.39 % | ||||
Current Valuation | 51.41 B | ||||
Shares Outstanding | 601.93 M | ||||
Shares Owned By Insiders | 0.88 % | ||||
Shares Owned By Institutions | 84.00 % | ||||
Number Of Shares Shorted | 10.38 M | ||||
Price To Earning | 32.77 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Edwards Lifesciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Edwards Lifesciences' short interest history, or implied volatility extrapolated from Edwards Lifesciences options trading.
Pair Trading with Edwards Lifesciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Edwards Lifesciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Edwards Lifesciences will appreciate offsetting losses from the drop in the long position's value.Moving against Edwards Stock
0.66 | SINT | SINTX Technologies | PairCorr |
0.59 | BBLG | Bone Biologics Corp Financial Report 20th of May 2024 | PairCorr |
0.52 | HCAT | Health Catalyst Financial Report 14th of May 2024 | PairCorr |
0.51 | RSLS | ReShape Lifesciences | PairCorr |
0.45 | CMAX | CareMax Trending | PairCorr |
The ability to find closely correlated positions to Edwards Lifesciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Edwards Lifesciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Edwards Lifesciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Edwards Lifesciences Corp to buy it.
The correlation of Edwards Lifesciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Edwards Lifesciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Edwards Lifesciences Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Edwards Lifesciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Other Tools for Edwards Stock
When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |